Expand Your Treatment Focus with the TearCare® System

Expand Your Treatment Focus with the TearCare® System

Treating Dry Eye Disease (DED) starts with Meibomian Gland Disease (MGD)

Your Peers Agree, Obstruction is a Catalyst for MGD-related Dry Eye

87% believe obstruction is a key component of MGD1
71% state obstruction removal should be the first-line treatment for patients with MGD1
Yet only 5.2% of patients receive thermal expression treatment2
Learn more about the TearCare® System.

To address evaporative dry eye, you have to target the underlying cause—MGD. The TearCare® System is a heat and expression device designed to leverage intelligent therapeutic heat and your expertise in expression to evacuate obstructions.

The Future is Clear

The TearCare® System is the only heat and expression device designed to evacuate obstructed meibomian glands in treating MGD while harnessing a natural blink experience

TEARCARE SmartLids®

  • Optimal targeted heat 41° to 45°C for up to 15 minutes
  • Open-eye design for natural blinking
  • Universal fit

Clearance Assistant™

  • Meibomian gland expression
  • Real-time visualization
  • Precise gland targeting

TEARCARE SmartHub™

  • Highly Portable
  • Brainpower behind consistent heat
  • Monitors temperature 240x per second
A Treatment Patients Love to Experience

8 out of 10 patients say TearCare® is comfortable.3

of patients would likely recommend TearCare®  to family and friends.3

References:

  1. Survey of optometrists and ophthalmologists conducted by PentaVision LLC, publishers of Optometric Management and Ophthalmology Management from October 7, 2020 through November 5, 2020, and January through April 2012, Data on file.
  2. Market Scope 2021 Ocular Surface Disease Survey
  3. TearCare®. (2021). Opt-in patient rebate survey (January 2021 – July 2021) [Data on file]. Sight Sciences Inc.

Indications for Use: The TearCare® System is intended for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands. 
The TearCare® System may not be right for everyone. Please see Instructions for Use or visit TearCare.com for Contraindications, Warnings, Precautions and Adverse Events.

SightSciences_Logo_White_2410x880
  • 4040 Campbell Ave, Suite 100
  • Menlo Park CA 94025
  • T: 877-266-1144

© 2022 Sight Sciences, Inc.      2/22     TC-1697-US.v2